Simbionix to Exhibit New Lap Mentor Nephrectomy Module at the Upcoming SAGES Annual Meeting

March 24, 2011

CLEVELAND, March 24, 2011 /PRNewswire/ — Simbionix USA Corporation, the
world’s leading provider of medical education and simulation technology, is
happy to announce the release of their new Laparoscopic Nephrectomy module
for the LAP Mentor simulator. Hands-on practice of this complex module will
be available at the SAGES Annual Meeting between March 30 – April 2, 2011, at
Simbionix booth #240 and in the Learning Center.

It has been estimated to take surgeons approximately 15 laparoscopic
nephrectomy cases to become proficient with this procedure. The nephrectomy
complete procedure module is intended to provide an alternative platform for
shortening the learning curve involved with these procedures, in a risk-free
environment, before proceeding to the clinical setting. The module has been
designed to accommodate various procedure techniques, allowing trainees to
choose their preferred method of action.

“We are very excited to add the complex nephrectomy training module to
our LAP Mentor’s ever-growing library of modules,” said Mr. Ran Bronstein,
Simbionix President. “The true-to-life virtual reality simulation of this
highly advanced procedure is a breakthrough in simulation technology,
providing an environment abundant in anatomy layers which interact smoothly
with one another to simulate one continuous procedure. Simbionix continuously
overcomes technological challenges to provide the best training tools for the
medical community.”

About Simbionix USA Corporation

Simbionix is the world’s leading provider of simulation and training
products for medical professionals and the healthcare industry. Founded in
1997, the company is committed to delivering high quality products, advancing
clinical performance and optimizing procedural outcomes.

    For more information on Simbionix, visit http://www.simbionix.com

    Rebecca Zitter
    Manager of Marketing Communications and Distributor Relations

SOURCE Simbionix USA Corporation

Source: newswire

comments powered by Disqus